It provokes a strong immune response: the American vaccine from COVID-19 encouraged scientists

Moderna's stock soared after it announced that a potential vaccine to prevent COVID-19 elicited a “strong” immune response in all 45 patients in the early stages of human trials. Writes about this CNBC.

Photo: Shutterstock

Moderna shares rose more than 16%.

All 45 patients developed neutralizing antibodies, which, according to scientists, are important for creating immunity. This gives hope that the vaccine may provide some protection against coronavirus. In the study, each participant received a dose of 25, 100 or 250 micrograms, 15 people in each group. Participants received two doses of a potential vaccine.

After two shots, the vaccine produced a “strong” immune response in all participants, a company spokesperson said. The company said levels of neutralizing antibodies in patients in the high-dose group were four times higher than in recovered COVID-19 patients.

“These phase 1 data demonstrate that vaccination with mRNA-1273 induces a robust immune response regardless of dose. The company chose 100 mcg as the optimal dose for the phase 3 study, said Moderna Chief Medical Officer Tal Zaks. “We look forward to commencing the Phase 3 study of mRNA-1273 this month to demonstrate the ability of our vaccine to significantly reduce the risk of COVID-19 disease.”

In May, the company released preliminary information about the early stages of testing, but the data were insufficient, and therefore the study has not yet been reviewed.

The company said the vaccine was generally well tolerated, but more than half of the participants reported mild or moderate symptoms, such as fatigue, muscle pain, or pain at the injection site.

On the subject: Why the coronavirus vaccine has been developed for so long: a scientific explanation

Evaluation of the resistance of the immune response continues, and participants will be monitored for one year after vaccination.

According to data compiled by Johns Hopkins University, Moderna is one of several developers of a potential vaccine against COVID-19. According to the World Health Organization (WHO), more than 100 vaccines are being developed in the world.

Moderna previously announced that it will begin testing the vaccine on July 27. The study will bring together 30 participants in 000 cities. Participants in the experimental group will receive a dose of 87 μg of the potential vaccine on the first day and after another 100 days. Some patients will also receive a placebo.

Moderna's experimental vaccine contains genetic material called messenger RNA, or mRNA. mRNA is the genetic code that tells cells what to build—in this case, an antigen that can trigger an immune response to a virus.

Scientists are still studying key aspects of the virus, including how the immune system reacts when a person becomes infected. The answers, they said, could have important implications for developing a vaccine, including how quickly it could be distributed to the public.

The United States plans to distribute 300 million doses of the COVID-19 vaccine by early 2021.

Dr. Anthony Fauci, the country's leading infectious disease specialist, has often praised the potential vaccine for Moderna. He said scientists could create at least one safe and effective vaccine by the end of the year or early 2021.

Read also on ForumDaily:

Scientist: asymptomatic COVID-19 does not exist, and coronavirus is a common seasonal disease

Why the coronavirus vaccine has been developed for so long: a scientific explanation

Permanently or permanently: for how long can complications remain after coronavirus?

Loss of memory, amputation of fingers, panic attacks: how COVID-19 changed the life of recovered

Do you want more important and interesting news about life in the USA and immigration to America? — support us donate! Also subscribe to our page Facebook. Select the “Priority in display” option and read us first. Also, don't forget to subscribe to our РєР ° РЅР ° Р »РІ Telegram  and Instagram- there is a lot of interesting things there. And join thousands of readers ForumDaily New York — there you will find a lot of interesting and positive information about life in the metropolis.